Chugai Pharmaceutical
This sponsor has funded 2 studies across 2 countries.
| EU PAS ID | Status | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|
| 13205 | Finalised | Incidence and pattern description of gastrointestinal, skin, genital, corneal, and mucosal erosions, ulcerations, perforations, haemorrhages,... | Yes | No |
| 25131 | Finalised | Survival follow up of JO25567, a randomized phase 2 study comparing erlotinib and bevacizumab combination with erlotinib alone in NSCLC patients... | Yes | Yes |
PAS by Risk Management Plan (RMP) requirement
Chugai Pharmaceutical
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
Chugai Pharmaceutical
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
Chugai Pharmaceutical
2 Study countries specified are the following:
- Japan
- United Kingdom